Abstract
Primary neuroendocrine carcinoma of the bladder is an aggressive disease with significant metastatic potential. It is an extremely rare variation of non-urothelial carcinoma of the bladder, accounting for < 1% [1]. Given its rarity, no therapeutic consensus has been codified to date. We report a retrospective series of five cases and detail their anatomoclinical and therapeutic aspects.
Highlights
Primary neuroendocrine carcinoma of the bladder is an aggressive disease with significant metastatic potential
We report a retrospective series of five cases and detail their anatomoclinical and therapeutic aspects
The incidence of neuroendocrine carcinomas of the bladder is increasing due to the diagnostic progress by immunohistochemical means available today. They are often diagnosed at a stage that is already locally advanced or metastatic; their evolution is very rapid and their prognosis is poor
Summary
Primary neuroendocrine carcinoma of the bladder is an aggressive disease with significant metastatic potential It is an extremely rare variation of non-urothelial carcinoma of the bladder, accounting for < 1% [1]. No therapeutic consensus has been codified to date. It is an extremely rare variation of nonurothelial bladder carcinoma, accounting for < 1% [1]. We report a retrospective series of five cases of neuroendocrine carcinoma and we detail the anatomoclinical and therapeutic aspects through a study of the literature According to the WHO classification 2016, neuroendocrine carcinoma of the bladder includes; small cell neuroendocrine carcinoma (SCNEC) which is the most common subtype, large cell neuroendocrine carcinoma (LCNEC), paraganglioma and well differentiated neuroendocrine tumor [2,3,4].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call